Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Insights, Forecast to 2029
This report presents an overview of global market for Chemotheraphy-induced Nausea and Vomitting Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Chemotheraphy-induced Nausea and Vomitting Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chemotheraphy-induced Nausea and Vomitting Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chemotheraphy-induced Nausea and Vomitting Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Chemotheraphy-induced Nausea and Vomitting Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories and Baxter Healthcare, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Chemotheraphy-induced Nausea and Vomitting Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotheraphy-induced Nausea and Vomitting Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Chemotheraphy-induced Nausea and Vomitting Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chemotheraphy-induced Nausea and Vomitting Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chemotheraphy-induced Nausea and Vomitting Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Chemotheraphy-induced Nausea and Vomitting Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories and Baxter Healthcare, etc.
By Company
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck & Co
- Tesaro
- Acacia Pharma
- Aphios
- Barr Laboratories
- Baxter Healthcare
- Eisai
- Especificos Stendhal
- F.Hoffmann La Roche
- Mundipharma
- Mylan Pharmaceuticals
- OPKO Health
- Orchid Healthcare
- Aloxi (Palonosetron)
- Kytril (Granisetron)
- Emend (Aprepitant)
- Others
- Acute Nausea and Vomitting Treatment
- Delayed Nausea and Vomitting Treatment
- Anticipatory Nausea and Vomitting Treatment
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Chemotheraphy-induced Nausea and Vomitting Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotheraphy-induced Nausea and Vomitting Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Aloxi (Palonosetron)
1.2.3 Kytril (Granisetron)
1.2.4 Emend (Aprepitant)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Acute Nausea and Vomitting Treatment
1.3.3 Delayed Nausea and Vomitting Treatment
1.3.4 Anticipatory Nausea and Vomitting Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2018-2029)
2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2018-2023)
2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2024-2029)
2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Chemotheraphy-induced Nausea and Vomitting Treatment by Players
3.1.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2018-2023)
3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2022
3.5 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment Head office and Area Served
3.6 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
3.7 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CHEMOTHERAPHY-INDUCED NAUSEA AND VOMITTING TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2018-2023)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2024-2029)
5 CHEMOTHERAPHY-INDUCED NAUSEA AND VOMITTING TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2018-2023)
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
6.4.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
7.4.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
8.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
8.2.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
8.2.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
8.2.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
8.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
8.3.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
8.3.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
8.3.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
9.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
9.2.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
9.2.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
9.2.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
9.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
9.3.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
9.3.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
9.3.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
9.4 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
9.4.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023)
9.4.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.1.5 GlaxoSmithKline Recent Developments
11.2 Helsinn
11.2.1 Helsinn Company Details
11.2.2 Helsinn Business Overview
11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.2.5 Helsinn Recent Developments
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Details
11.3.2 Heron Therapeutics Business Overview
11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.3.5 Heron Therapeutics Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Details
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.4.5 Merck & Co Recent Developments
11.5 Tesaro
11.5.1 Tesaro Company Details
11.5.2 Tesaro Business Overview
11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.5.5 Tesaro Recent Developments
11.6 Acacia Pharma
11.6.1 Acacia Pharma Company Details
11.6.2 Acacia Pharma Business Overview
11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.6.5 Acacia Pharma Recent Developments
11.7 Aphios
11.7.1 Aphios Company Details
11.7.2 Aphios Business Overview
11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.7.5 Aphios Recent Developments
11.8 Barr Laboratories
11.8.1 Barr Laboratories Company Details
11.8.2 Barr Laboratories Business Overview
11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.8.5 Barr Laboratories Recent Developments
11.9 Baxter Healthcare
11.9.1 Baxter Healthcare Company Details
11.9.2 Baxter Healthcare Business Overview
11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.9.5 Baxter Healthcare Recent Developments
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.10.5 Eisai Recent Developments
11.11 Especificos Stendhal
11.11.1 Especificos Stendhal Company Details
11.11.2 Especificos Stendhal Business Overview
11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.11.5 Especificos Stendhal Recent Developments
11.12 F.Hoffmann La Roche
11.12.1 F.Hoffmann La Roche Company Details
11.12.2 F.Hoffmann La Roche Business Overview
11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.12.5 F.Hoffmann La Roche Recent Developments
11.13 Mundipharma
11.13.1 Mundipharma Company Details
11.13.2 Mundipharma Business Overview
11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.13.5 Mundipharma Recent Developments
11.14 Mylan Pharmaceuticals
11.14.1 Mylan Pharmaceuticals Company Details
11.14.2 Mylan Pharmaceuticals Business Overview
11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.14.5 Mylan Pharmaceuticals Recent Developments
11.15 OPKO Health
11.15.1 OPKO Health Company Details
11.15.2 OPKO Health Business Overview
11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.15.5 OPKO Health Recent Developments
11.16 Orchid Healthcare
11.16.1 Orchid Healthcare Company Details
11.16.2 Orchid Healthcare Business Overview
11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.16.5 Orchid Healthcare Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Aloxi (Palonosetron)
1.2.3 Kytril (Granisetron)
1.2.4 Emend (Aprepitant)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Acute Nausea and Vomitting Treatment
1.3.3 Delayed Nausea and Vomitting Treatment
1.3.4 Anticipatory Nausea and Vomitting Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2018-2029)
2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2018-2023)
2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2024-2029)
2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Chemotheraphy-induced Nausea and Vomitting Treatment by Players
3.1.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2018-2023)
3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2022
3.5 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment Head office and Area Served
3.6 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
3.7 Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CHEMOTHERAPHY-INDUCED NAUSEA AND VOMITTING TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2018-2023)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2024-2029)
5 CHEMOTHERAPHY-INDUCED NAUSEA AND VOMITTING TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2018-2023)
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
6.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
6.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
6.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
6.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
6.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
6.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
6.4.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
7.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
7.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
7.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
7.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
7.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
7.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
7.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
7.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
7.4.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
8.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
8.2.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
8.2.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
8.2.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
8.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
8.3.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
8.3.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
8.3.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
9.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
9.2.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
9.2.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
9.2.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
9.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
9.3.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
9.3.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
9.3.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
9.4 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
9.4.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023)
9.4.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.1.5 GlaxoSmithKline Recent Developments
11.2 Helsinn
11.2.1 Helsinn Company Details
11.2.2 Helsinn Business Overview
11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.2.5 Helsinn Recent Developments
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Details
11.3.2 Heron Therapeutics Business Overview
11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.3.5 Heron Therapeutics Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Details
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.4.5 Merck & Co Recent Developments
11.5 Tesaro
11.5.1 Tesaro Company Details
11.5.2 Tesaro Business Overview
11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.5.5 Tesaro Recent Developments
11.6 Acacia Pharma
11.6.1 Acacia Pharma Company Details
11.6.2 Acacia Pharma Business Overview
11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.6.5 Acacia Pharma Recent Developments
11.7 Aphios
11.7.1 Aphios Company Details
11.7.2 Aphios Business Overview
11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.7.5 Aphios Recent Developments
11.8 Barr Laboratories
11.8.1 Barr Laboratories Company Details
11.8.2 Barr Laboratories Business Overview
11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.8.5 Barr Laboratories Recent Developments
11.9 Baxter Healthcare
11.9.1 Baxter Healthcare Company Details
11.9.2 Baxter Healthcare Business Overview
11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.9.5 Baxter Healthcare Recent Developments
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.10.5 Eisai Recent Developments
11.11 Especificos Stendhal
11.11.1 Especificos Stendhal Company Details
11.11.2 Especificos Stendhal Business Overview
11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.11.5 Especificos Stendhal Recent Developments
11.12 F.Hoffmann La Roche
11.12.1 F.Hoffmann La Roche Company Details
11.12.2 F.Hoffmann La Roche Business Overview
11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.12.5 F.Hoffmann La Roche Recent Developments
11.13 Mundipharma
11.13.1 Mundipharma Company Details
11.13.2 Mundipharma Business Overview
11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.13.5 Mundipharma Recent Developments
11.14 Mylan Pharmaceuticals
11.14.1 Mylan Pharmaceuticals Company Details
11.14.2 Mylan Pharmaceuticals Business Overview
11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.14.5 Mylan Pharmaceuticals Recent Developments
11.15 OPKO Health
11.15.1 OPKO Health Company Details
11.15.2 OPKO Health Business Overview
11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.15.5 OPKO Health Recent Developments
11.16 Orchid Healthcare
11.16.1 Orchid Healthcare Company Details
11.16.2 Orchid Healthcare Business Overview
11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
11.16.5 Orchid Healthcare Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Aloxi (Palonosetron)
Table 3. Key Players of Kytril (Granisetron)
Table 4. Key Players of Emend (Aprepitant)
Table 5. Key Players of Others
Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2018-2023)
Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2024-2029)
Table 12. Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
Table 13. Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
Table 14. Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
Table 15. Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
Table 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Players (2018-2023)
Table 18. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2022)
Table 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Headquarters and Area Served
Table 22. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
Table 23. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2018-2023)
Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2018-2023)
Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2024-2029)
Table 33. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 65. GlaxoSmithKline Company Details
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 68. GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 69. GlaxoSmithKline Recent Developments
Table 70. Helsinn Company Details
Table 71. Helsinn Business Overview
Table 72. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 73. Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 74. Helsinn Recent Developments
Table 75. Heron Therapeutics Company Details
Table 76. Heron Therapeutics Business Overview
Table 77. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 78. Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 79. Heron Therapeutics Recent Developments
Table 80. Merck & Co Company Details
Table 81. Merck & Co Business Overview
Table 82. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 83. Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 84. Merck & Co Recent Developments
Table 85. Tesaro Company Details
Table 86. Tesaro Business Overview
Table 87. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 88. Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 89. Tesaro Recent Developments
Table 90. Acacia Pharma Company Details
Table 91. Acacia Pharma Business Overview
Table 92. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 93. Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 94. Acacia Pharma Recent Developments
Table 95. Aphios Company Details
Table 96. Aphios Business Overview
Table 97. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 98. Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 99. Aphios Recent Developments
Table 100. Barr Laboratories Company Details
Table 101. Barr Laboratories Business Overview
Table 102. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 103. Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 104. Barr Laboratories Recent Developments
Table 105. Baxter Healthcare Company Details
Table 106. Baxter Healthcare Business Overview
Table 107. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 108. Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 109. Baxter Healthcare Recent Developments
Table 110. Eisai Company Details
Table 111. Eisai Business Overview
Table 112. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 113. Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 114. Eisai Recent Developments
Table 115. Especificos Stendhal Company Details
Table 116. Especificos Stendhal Business Overview
Table 117. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 118. Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 119. Especificos Stendhal Recent Developments
Table 120. F.Hoffmann La Roche Company Details
Table 121. F.Hoffmann La Roche Business Overview
Table 122. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 123. F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 124. F.Hoffmann La Roche Recent Developments
Table 125. Mundipharma Company Details
Table 126. Mundipharma Business Overview
Table 127. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 128. Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 129. Mundipharma Recent Developments
Table 130. Mylan Pharmaceuticals Company Details
Table 131. Mylan Pharmaceuticals Business Overview
Table 132. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 133. Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 134. Mylan Pharmaceuticals Recent Developments
Table 135. OPKO Health Company Details
Table 136. OPKO Health Business Overview
Table 137. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 138. OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 139. OPKO Health Recent Developments
Table 140. Orchid Healthcare Company Details
Table 141. Orchid Healthcare Business Overview
Table 142. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 143. Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 144. Orchid Healthcare Recent Developments
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Aloxi (Palonosetron)
Table 3. Key Players of Kytril (Granisetron)
Table 4. Key Players of Emend (Aprepitant)
Table 5. Key Players of Others
Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2018-2023)
Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2024-2029)
Table 12. Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
Table 13. Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
Table 14. Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
Table 15. Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
Table 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Players (2018-2023)
Table 18. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2022)
Table 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Headquarters and Area Served
Table 22. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
Table 23. Global Key Players of Chemotheraphy-induced Nausea and Vomitting Treatment, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2018-2023)
Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2018-2023)
Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Application (2024-2029)
Table 33. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 65. GlaxoSmithKline Company Details
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 68. GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 69. GlaxoSmithKline Recent Developments
Table 70. Helsinn Company Details
Table 71. Helsinn Business Overview
Table 72. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 73. Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 74. Helsinn Recent Developments
Table 75. Heron Therapeutics Company Details
Table 76. Heron Therapeutics Business Overview
Table 77. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 78. Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 79. Heron Therapeutics Recent Developments
Table 80. Merck & Co Company Details
Table 81. Merck & Co Business Overview
Table 82. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 83. Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 84. Merck & Co Recent Developments
Table 85. Tesaro Company Details
Table 86. Tesaro Business Overview
Table 87. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 88. Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 89. Tesaro Recent Developments
Table 90. Acacia Pharma Company Details
Table 91. Acacia Pharma Business Overview
Table 92. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 93. Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 94. Acacia Pharma Recent Developments
Table 95. Aphios Company Details
Table 96. Aphios Business Overview
Table 97. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 98. Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 99. Aphios Recent Developments
Table 100. Barr Laboratories Company Details
Table 101. Barr Laboratories Business Overview
Table 102. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 103. Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 104. Barr Laboratories Recent Developments
Table 105. Baxter Healthcare Company Details
Table 106. Baxter Healthcare Business Overview
Table 107. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 108. Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 109. Baxter Healthcare Recent Developments
Table 110. Eisai Company Details
Table 111. Eisai Business Overview
Table 112. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 113. Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 114. Eisai Recent Developments
Table 115. Especificos Stendhal Company Details
Table 116. Especificos Stendhal Business Overview
Table 117. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 118. Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 119. Especificos Stendhal Recent Developments
Table 120. F.Hoffmann La Roche Company Details
Table 121. F.Hoffmann La Roche Business Overview
Table 122. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 123. F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 124. F.Hoffmann La Roche Recent Developments
Table 125. Mundipharma Company Details
Table 126. Mundipharma Business Overview
Table 127. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 128. Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 129. Mundipharma Recent Developments
Table 130. Mylan Pharmaceuticals Company Details
Table 131. Mylan Pharmaceuticals Business Overview
Table 132. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 133. Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 134. Mylan Pharmaceuticals Recent Developments
Table 135. OPKO Health Company Details
Table 136. OPKO Health Business Overview
Table 137. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 138. OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 139. OPKO Health Recent Developments
Table 140. Orchid Healthcare Company Details
Table 141. Orchid Healthcare Business Overview
Table 142. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 143. Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023) & (US$ Million)
Table 144. Orchid Healthcare Recent Developments
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type: 2022 VS 2029
Figure 3. Aloxi (Palonosetron) Features
Figure 4. Kytril (Granisetron) Features
Figure 5. Emend (Aprepitant) Features
Figure 6. Others Features
Figure 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2022 VS 2029
Figure 9. Acute Nausea and Vomitting Treatment Case Studies
Figure 10. Delayed Nausea and Vomitting Treatment Case Studies
Figure 11. Anticipatory Nausea and Vomitting Treatment Case Studies
Figure 12. Chemotheraphy-induced Nausea and Vomitting Treatment Report Years Considered
Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region: 2022 VS 2029
Figure 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players in 2022
Figure 17. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2022
Figure 19. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 21. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 22. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 23. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 27. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 28. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 29. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 37. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 38. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 40. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 41. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2018-2029)
Figure 42. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 52. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 59. Helsinn Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 60. Heron Therapeutics Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 61. Merck & Co Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 62. Tesaro Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 63. Acacia Pharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 64. Aphios Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 65. Barr Laboratories Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 66. Baxter Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 67. Eisai Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 68. Especificos Stendhal Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 69. F.Hoffmann La Roche Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 70. Mundipharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 71. Mylan Pharmaceuticals Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 72. OPKO Health Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 73. Orchid Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Figure 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type: 2022 VS 2029
Figure 3. Aloxi (Palonosetron) Features
Figure 4. Kytril (Granisetron) Features
Figure 5. Emend (Aprepitant) Features
Figure 6. Others Features
Figure 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2022 VS 2029
Figure 9. Acute Nausea and Vomitting Treatment Case Studies
Figure 10. Delayed Nausea and Vomitting Treatment Case Studies
Figure 11. Anticipatory Nausea and Vomitting Treatment Case Studies
Figure 12. Chemotheraphy-induced Nausea and Vomitting Treatment Report Years Considered
Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region: 2022 VS 2029
Figure 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players in 2022
Figure 17. Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2022
Figure 19. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 21. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 22. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 23. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 27. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 28. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 29. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 37. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 38. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 40. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 41. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2018-2029)
Figure 42. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2018-2029)
Figure 52. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 59. Helsinn Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 60. Heron Therapeutics Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 61. Merck & Co Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 62. Tesaro Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 63. Acacia Pharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 64. Aphios Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 65. Barr Laboratories Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 66. Baxter Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 67. Eisai Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 68. Especificos Stendhal Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 69. F.Hoffmann La Roche Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 70. Mundipharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 71. Mylan Pharmaceuticals Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 72. OPKO Health Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 73. Orchid Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
